Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

In this article

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

After the launch of the first-ever GLP-1 pill for weight loss from Novo Nordisk

this month, obesity was top of mind at the annual JPMorgan Healthcare Conference, which drew thousands of pharma and biotech companies, investors, advisors and analysts.

I sat down with Ray Stevens, the CEO of obesity market hopeful Structure Therapeutics

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Related reading

Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill…

Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the…

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug…

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli…

Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss…

What obesity drugmakers see next in the market: More pills, easier access and…